http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1108205-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d452ebbe234b18c80d0462dc24578da3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4722 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 1999-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eabecc4d72b6dc252232f43980cb9f65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4cbacd7cf77701c29530cb0ca06cbc5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1810c9db21d4679db0a71d4a72e8484b |
| publicationDate | 2001-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1108205-A2 |
| titleOfInvention | Azaftig, a proteoglycan for monitoring cachexia and for control of obesity |
| abstract | A proteoglycan ("azaftig") with a molecular weight of approximately 24,000 Dalton has been isolated and partially characterized from the urine of cachectic cancer and non-cancer patients. Azaftig has been shown to bind to receptors on fat cell membranes, and to cause lipolysis. Azaftig does not bind to muscle cell membranes, or cause proteolysis in muscle tissue. Azaftig detection in urine or other body fluids will allow early identification of patients in which weight loss may become a problem. Azaftig may also aid fat loss in humans in which obesity is a threat to health. |
| priorityDate | 1998-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 520.